TrialCancer science2012

Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy.

Yachiyo Kuwatsuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.